OCC Orthocell

Orthocell Appoints Surgical Specialties as Exclusive Distributor

PERTH, Australia--(BUSINESS WIRE)--

Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has appointed Surgical Specialties Pty Ltd (Surgical Specialties) as its exclusive distributor in Australia and New Zealand for its world leading cell therapies for tendon regeneration (Ortho-ATI®) and cartilage regeneration (Ortho-ACI®).

“Surgical Specialties is a leading distributor of innovative medical devices and one of the few local companies with its own national sales force and marketing teams,” said Managing Director of Orthocell, Paul Anderson. “Surgical Specialties is the ideal partner with established relationships with leading orthopaedic surgeons and sports physicians, a successful track record and a highly skilled and dedicated national sales force,” he added.

Surgical Specialties will take over distribution responsibilities for Orthocell’s cell therapies including targeted promotion activities and initiating sales, as well as assisting with expanding the network of referring doctors and physicians. The exclusive distribution agreement has a term of five years and the arrangement will allow Orthocell to maintain its focus on the development of its novel regenerative medicine products and driving national and international regulatory approvals for its technologies.

“We are very excited to be involved with Orthocell. Orthocell has the only cell therapy intervention listed on the Australian Register of Therapeutic Goods (ARTG) for the repair of damaged or degenerate cartilage in the knee or ankle joint, and an innovative market leading approach for the repair of degenerate tendons. Both products are based on ground-breaking technology and addresses a significant clinical need, particularly in the orthopaedic and sports physician market,” said CEO of Surgical Specialties, Phil Nicholl.

About Surgical Specialties Pty Ltd:

Established in 2006, Surgical Specialties now has a team of over 70 people, with sales offices throughout Australia and New Zealand. Surgical Specialties is an independent distributor of innovative medical devices to the Australian and New Zealand medical community. The business focuses on the following surgical areas: Arthroplasty, Extremities, Specialty Trauma, Orthobiologics, Critical Care and Operating Room Products.

EN
11/10/2017

Underlying

OCCOrthocell

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orthocell

Free Trial
OCC ORTHOCELL

Orthocell Ltd: 2 directors

Two Directors at Orthocell Ltd sold 1,570,618 shares at 0.479AUD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...

09/24/21 September 24, 2021 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Positive Pre-Clinical Results Using CelGro® in Anterior Cruciate Liga...

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC) (“Orthocell” or the “Company”) is pleased to announce positive pre-clinical results using CelGro® collagen rope for Anterior Cruciate Ligament (ACL) reconstruction. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180204005104/en/ Figure 1 - An illustration depicting a ruptured ACL (Graphic: Business Wire) Orthocell Managing Director Paul Anderson said: “We are extremely exci...

February 5, 2018 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Orthocell Secures New Patent for Suture-Less Repair of Soft Tissue

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a further Australian patent for its CelGro® collagen medical device platform for soft tissue regeneration and repair applications. The patent entitled “Suture-less repair of soft tissue” provides additional important intellectual property to protect the CelGro® product platform. Orthocell Managing Director Paul Anderson said: “This is an important addition to ou...

January 18, 2018 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Orthocell Granted European Tendon Regeneration Patent

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce it has been granted a key European Patent. The patent is entitled ‘Culture medium, culturing method and use of tenocytes’ protecting the method of manufacturing tendon regeneration cells (Tenocytes) to form the Autologous Tenocyte Implantation (Ortho-ATI®) product. The patent expires in 2027 and provides additional important intellectual property (IP) to protect Orthocell’s tendon repair ap...

December 15, 2017 1 EN
 PRESS RELEASE
Free
OCC ORTHOCELL

Orthocell Commences Treatment of Its 1,000th Patient

PERTH, Australia--(BUSINESS WIRE)-- Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce that it has commenced treatment of its 1,000th patient, in its TGA licensed manufacturing facility using the Company’s proprietary tissue engineering process, developed in conjunction with Professor Minghao Zheng and the University of Western Australia. This marks a significant milestone in the Company’s history as it continues to clinically validate its market leading regenerative medicine...

December 7, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch